Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).

Schachter, Jacob; Ribas, Antoni; Long, Georgina V; Arance, Ana; Grob, Jean-Jacques; Mortier, Laurent; Daud, Adil; Carlino, Matteo S; McNeil, Catriona; Lotem, Michal; Larkin, James; Lorigan, Paul; Neyns, Bart; Blank, Christian; Petrella, Teresa M; Hamid, Omid; Zhou, Honghong; Ebbinghaus, Scot; Ibrahim, Nageatte; Robert, Caroline.
Lancet; 390(10105): 1853-1862, 2017 Oct 21.
Artigo em Inglês | MEDLINE | ID: mdl-28822576